🚀 Level up your imaging-based #Toxicology studies with #ContractResearch services from the #NikonBioImagingLabUSA.

🧑‍🔬 Our expert team can design #Microscopy-based #HighContent assays and help you generate robust data.

🔗 Contact us today: bit.ly/42IIPsU

#CRO #Biotech #Microscope #Imaging

🧑‍🔬 At the #NikonBioImagingLabUSA we provide expert #ContractResearch support for both 2D and 3D #Microscope #Imaging across a range of #LifeScience applications, including both live and fixed cells experiments.

🔗 Learn more about our #CRO services: bit.ly/45Zwym6

🔬 Need a reliable automated #HighContent #Microscopy solution?

✨ The #NikonBioImagingLab is your expert #ContractResearch partner for sensitive imaging applications. Turnkey assays are available with our ECLIPSE Ji Smart Imaging System.

🔗 Learn more: bit.ly/47vD3y0

#CRO #Microscope #Imaging

🧑‍🔬 #SpatialBiology is a core focus at the #NikonBioImagingLabUSA, where we provide comprehensive multi-omics service.

🔬 We support high-plex immunofluorescence and whole transcriptome spatial profiling, and more.

🔗 About our #ContractResearch services: bit.ly/41bM4ID

#Microscopy #CRO

Contract research firms’ strong earnings signal stabilizing biotech, pharma spending By Sneha S K (Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a cautious stretch driven by tighter sector financing. Danaher (NYSE:DHR), Medpace, IQVIA, ICON and Thermo Fisher (NYSE:TMO) have posted strong results owing to steady demand from the industry for tools and services that are used in the development of novel medicines. "Biotech funding has started to tick up month over month from April to June, and perhaps our biggest takeaway from IQVIA results as well as Medpace is that the macro environment, while still challenged, has perhaps stabilized," said TD Cowen analyst Charles Rhyee. Contract drug manufacturers witnessed reduced spending from biotech clients in the past two years, hurt by a slump in investor funding and higher interest rates. The S&P Biotech ETF index hit an 18-month low in April and is trading at about half its 2021 peak. Analysts had initially feared that recent policy changes under U.S. President Donald Trump’s administration such as potential tariffs on pharmaceuticals and a trade war with China could further squeeze R&D budgets across the sector. Several CROs also operate in the country, and count biotechs there as clients. China is also a key source of raw ingredients and supplies for the pharmaceutical and medical device industries. However, CRO executives flagged robust demand across regions for their drug development products such as instruments and analytical tools used in trials and manufacturing. Some companies also experienced fewer order cancellations than initially expected, with IQVIA’s CEO Ari Bousbib saying their clients "continued launching new drugs despite the uncertainty". IQVIA’s results point to a potential inflection in its biopharma demand environment, which would bode well as we enter 2026, said Evercore ISI analyst Elizabeth Anderson. Medpace raised its full-year revenue expectations by $280 million at the midpoint, citing better-than-expected funding, fewer cancellations and accelerated decision-making. "Although funding challenges remain acute for many of our clients, the large majority of those clients with ongoing studies were able to obtain sufficient funding to keep the trials running. The funding environment has been stable to improved," said Medpace CEO August Troendle. "CRO results thus far indicate an improving end-market... However, we do not yet have high conviction that clinical trial demand has returned to full health," Leerink Partners analyst Michael Cherny said.

Click Subscribe. #Biotech #Pharma #ContractResearch #Earnings #Healthcare

🧑‍🔬🔬At the #NikonBioImagingLabUSA we have the tools and expertise for high performance volumetric imaging, analysis, and visualization of popular 3D models, including #OrganOnChip and #Organoids.

🔗 Learn more about this and our other #ContractResearch services: bit.ly/3Io51kP

#CRO #Microscopy

🧑‍🔬 At the #NikonBioImagingLabUSA we can design and perform sophisticated #WholeSlideImaging #Microscopy workflows, including experiments where regions of interest are automatically revisited for detailed high resolution 3D imaging.

🔗 Learn more: bit.ly/3ZPkEHZ

#NikonMicroscopy #ContractResearch

📣 Announcing a new collaboration with the Astellas SakuLab™-Cambridge MA whereby resident companies will receive access to advanced imaging systems, analysis capabilities, and #ContractResearch services at the Nikon BioImaging Lab USA!

🔗 Learn more: bit.ly/4kLy6F7

#NikonMicroscopy #Microscopy

🧬 Understanding how drugs work at the molecular level is important for #DrugDevelopment. #smFISH is used to quantify how drugs impact mRNA expression.

🔗 Our #NikonBioImagingLabUSA team has extensive smFISH experience and are ready to assist you: bit.ly/45VeIAX

#CRO #ContractResearch #Microscopy

Contract Research Global Access Diagnostics (GADx) offers a comprehensive range of lateral flow immunoassay development services to researchers, developers an…

Need a FAST way to develop your next rapid test? 🚨 GADx’s contract research team can handle everything, from reagents to device design & validation! 🧪

➡️zurl.co/CDGEE

#lateralflow #immunoassay #R&D #contractresearch

Instagram: bit.ly/4k7ki75
Threads: bit.ly/44ZYPbS
YouTube: bit.ly/44Y8boz
Twitter: bit.ly/44Nf64b

#NikonBioImagingLabUSA is now on LinkedIn! Follow to keep up to date with our #ContractResearch #CRO services: bit.ly/4iNkPe6
(3/3)